Experimental Medicine INitiative to Explore New Therapies (EMINENT) network training programme

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Experimental medicine lies at the core of MRC translational research strategy, translating basic scientific discovery into benefits for human health. Delivering effective experimental medicine requires the involvement of clinicians and scientists with bespoke skills sets; integrating mechanistic disease insight with experience of drug development and clinical trial design, for which a critical skills gap has been identified by the MRC. A key objective of EMINENT is to address this skills gap with the specific aim to ‘Develop a cohort of excellence in experimental medicine, through targeted training for early career scientists and fellows’. This cohort of clinical and non-clinical scientists, will be unique within the UK, and consist of individuals who will have the aptitude, training, experience and skill set to allow them to work between academia and the pharmaceutical industry to deliver high quality, integrated experimental medicine studies and early phase clinical trials. To capitalize on the opportunity created by EMINENT, the MRC, GSK and five partnership Universities (UCL, Glasgow, Cambridge, Newcastle and Imperial), together with the NIHR, wish to establish a formal EMINENT Training Programme in which all EMINENT-funded technical, post-doctoral and clinical research staff, will be expected to participate. This includes the additional five NIHR-BRC and GSK funded Clinical Research Fellowship posts, which will be established at Cambridge, UCL, Imperial, Newcastle and (with EMINENT support) Glasgow University.